EPB41L2

Across TCGA pan-cancer cohorts, EPB41L2 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EPB41L2 data layer compared with 21 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher EPB41L2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated EPB41L2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, LUSC, and CESC are the cancer types where EPB41L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.841	0.627	.006	30	view →
LUSC	OS	Median	All	0.278	0.737	<.001	27	view →
CESC	DFS	Median	III,IV	0.053	0.729	<.001	18	view →
LGG	OS	Median	All	0.173	0.810	<.001	12	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
KIRC	OS	Median	All	0.249	0.810	.011	6	view →
STAD	OS	Median	IV	1.000	0.299	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EPB41L2–UCEC (DFS)

Open the UCEC breakdown →